RESUMEN
BACKGROUND: Although generalized anxiety disorder (GAD) and major depressive episode (MDE) are known to be highly co-morbid, little prospective research has examined whether these two disorders predict the subsequent first onset or persistence of the other or the extent to which other predictors explain the time-lagged associations between GAD and MDE. METHOD: Data were analyzed from the nationally representative two-wave panel sample of 5001 respondents who participated in the 1990-1992 National Comorbidity Survey (NCS) and the 2001-2003 NCS follow-up survey. Both surveys assessed GAD and MDE. The baseline NCS also assessed three sets of risk factors that are considered here: childhood adversities, parental history of mental-substance disorders, and respondent personality. RESULTS: Baseline MDE significantly predicted subsequent GAD onset but not persistence. Baseline GAD significantly predicted subsequent MDE onset and persistence. The associations of each disorder with the subsequent onset of the other attenuated with time since onset of the temporally primary disorder, but remained significant for over a decade after this onset. The risk factors predicted onset more than persistence. Meaningful variation was found in the strength and consistency of associations between risk factors and the two disorders. Controls for risk factors did not substantially reduce the net cross-lagged associations of the disorders with each other. CONCLUSIONS: The existence of differences in risk factors for GAD and MDE argues against the view that the two disorders are merely different manifestations of a single underlying internalizing syndrome or that GAD is merely a prodrome, residual, or severity marker of MDE.
Asunto(s)
Trastornos de Ansiedad/epidemiología , Trastorno Depresivo Mayor/epidemiología , Adolescente , Adulto , Trastornos de Ansiedad/diagnóstico , Niño , Hijo de Padres Discapacitados/psicología , Hijo de Padres Discapacitados/estadística & datos numéricos , Estudios de Cohortes , Comorbilidad , Trastorno Depresivo Mayor/diagnóstico , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Estudios de Seguimiento , Encuestas Epidemiológicas , Humanos , Persona de Mediana Edad , Personalidad/clasificación , Determinación de la Personalidad , Prevalencia , Pronóstico , Estudios Prospectivos , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Recurrencia , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de TiempoRESUMEN
INTRODUCTION: As with a number of emotional disorders, premenstrual complaints lie on a continuum dictated by severity, number and type of symptoms experienced. Women with premenstrual dysphoric disorder (PMDD) generally constitute the most symptomatic subgroup among those experiencing premenstrual symptoms. Included in the Diagnostic and Statistical Manual IV (DSM-IV) criteria for PMDD is a requirement for a minimum of 5 symptoms and for confirmation of these symptoms over two months by concurrent symptom ratings. These requirements likely influence critical patient characteristics rendering trial participants and typical patients seeking treatment, very different. METHODS: Women were recruited from 6 primary care obstetric-gynecological practices for participation in an open trial assessing the effectiveness of a serotonin reuptake inhibitor as a treatment for subsyndromal (3-4 symptoms) and syndromal (>4 symptoms) PMDD. Women were screened with the Brief Patient Health Questionnaire and Last Menstrual Period Module. Eligible women were invited to chart symptoms daily for one cycle using the Daily Record of Severity of Problems. Current comorbidity was allowed if women experienced a cyclic change in mood and behavioral symptoms. RESULTS: 47% of 904 women screened in practice settings (n=426) endorsed current PMS symptoms. Of this group, 174 (41%) were not interested in receiving treatment through a research study, 152 (36%) were not eligible to receive treatment (symptoms not severe enough, subsequently declined premenstrual symptom worsening, were already taking a psychotropic or wanted to conceive), 10% were lost to follow-up or had incomplete questionnaires, and 41 (10%) agreed to chart. Of women who charted, 9 (22%) verified symptoms. 93 women (22% of the 426) had comorbid MDD, 23 (5.4%) had minor depressive disorder and 61 (14%) had panic disorder. 24% of women with possible PMDD endorsed suicidal thoughts at any level (several days, more than half the days or every day); 20% endorsed these thoughts for several days. These results are used as a springboard to discuss how treatment results from efficacy trials may differ from treatment results that include women seeking treatment in usual care settings. CONCLUSION: These preliminary findings show that many women in primary care ob-gyn settings endorse serious premenstrual symptoms and have concurrent psychiatric conditions. Despite this, interest in study participation was low. This occurred even though the current study employed procedures that were much less rigorous than those used in the typical efficacy study. More work is needed to explore how the selectivity of patients included in clinical trials may bias estimates of how effective many agents will be in actual clinical practice.
Asunto(s)
Aceptación de la Atención de Salud , Selección de Paciente , Síndrome Premenstrual/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Adulto , Connecticut , Trastorno Depresivo/complicaciones , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Femenino , Humanos , Síndrome Premenstrual/complicaciones , Escalas de Valoración Psiquiátrica , Autoevaluación (Psicología) , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Resultado del TratamientoAsunto(s)
Fase Luteínica/fisiología , Sueño REM/fisiología , Adulto , Trastorno Depresivo/complicaciones , Trastorno Depresivo/fisiopatología , Femenino , Humanos , Polisomnografía , Valor Predictivo de las Pruebas , Valores de Referencia , Trastornos del Sueño-Vigilia/etiología , Trastornos del Sueño-Vigilia/fisiopatologíaRESUMEN
OBJECTIVE: Postpartum depressive disorders lead to maternal disability and disturbed mother-infant relationships, but information regarding the rates of major depressive disorder in minority women is noticeably lacking. The goal of this study was to determine whether the risk factors for and rate of postpartum major depressive disorder in a predominantly African American and Hispanic clinic population would be similar to those reported for Caucasian women. METHOD: Investigators systematically screened all women scheduled for their first postpartum visit on selected days at four publicly funded inner-city community maternal health clinics in Dallas County (N=802). A multistage screening process included the Edinburgh Postnatal Depression Scale, the Inventory of Depressive Symptomatology, and the Structured Clinical Interview for DSM-IV for a maximum of three assessments during the initial 3-5-week postpartum period. RESULTS: The estimated rate of major depressive disorder during the postpartum period among women in this setting was between 6.5% and 8.5%. Only 50% of the depressed women reported onset following birth. Bottle-feeding and not living with one's spouse or significant other were associated with depression at the first evaluation; persistent depressive symptoms were linked with the presence of other young children at home. Greater severity of depressive symptoms at first contact predicted major depressive disorder several weeks later. CONCLUSIONS: Rates of postpartum depression among Latina and African American postpartum women are similar to epidemiologic rates for Caucasian postpartum and nonpostpartum women. As previously shown for Caucasian women, major depressive disorder in many Latina and African American postpartum women begins before delivery, revealing the need to screen pregnant women for depression.
Asunto(s)
Depresión Posparto/epidemiología , Población Urbana/estadística & datos numéricos , Adulto , Depresión Posparto/diagnóstico , Depresión Posparto/psicología , Progresión de la Enfermedad , Etnicidad/estadística & datos numéricos , Femenino , Predicción , Humanos , Servicios de Salud Materna , Escalas de Valoración Psiquiátrica , Calidad de Vida , Índice de Severidad de la Enfermedad , Encuestas y CuestionariosRESUMEN
OBJECTIVE: To evaluate the efficacy and safety of venlafaxine, a new-generation antidepressant that selectively inhibits serotonin and norepinephrine reuptake, in the treatment of premenstrual dysphoric disorder (PMDD). METHOD: We conducted a randomized, double-blind, placebo-controlled, parallel-group, flexible-dose trial. After three screening cycles, including a single-blind placebo cycle, 164 women were randomly assigned to double-blind treatment with venlafaxine (50-200 mg/day) or placebo for four menstrual cycles. Primary outcome measures were the total premenstrual symptom scores as assessed by a daily symptom report (DSR) and the Hamilton Rating Scale for Depression. RESULTS: Venlafaxine was significantly more effective than placebo in reducing PMDD symptoms as assessed by DSR scores (P <.001 for last observation carried forward and observed analyses). Sixty percent of venlafaxine versus 35% of placebo subjects improved >50% (P =.003). Forty-three percent of venlafaxine subjects versus 25% of placebo subjects experienced symptom remission, defined as reduction of DSR scores to the postmenstrual level (P =.034). Venlafaxine treatment was significantly better than placebo for all statistically derived DSR factors (mood, function, pain, and physical symptoms). Improvement was relatively swift, with approximately 80% symptom reduction in the first treatment cycle. Mean venlafaxine doses ranged from 50 mg/day in the first treatment cycle to 130 mg/day in the fourth treatment cycle. Adverse events such as nausea, insomnia, and dizziness were mild and transient. CONCLUSIONS: Venlafaxine is significantly more efficacious than placebo for PMDD treatment. Response to treatment can occur in the first treatment cycle, and venlafaxine is well tolerated. Further studies are needed to evaluate the potential of intermittent (luteal phase) dosing for this cyclic disorder and the efficacy of long-term maintenance treatment with venlafaxine.
Asunto(s)
Ciclohexanoles/uso terapéutico , Síndrome Premenstrual/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Adulto , Método Doble Ciego , Femenino , Humanos , Síndrome Premenstrual/diagnóstico , Escalas de Valoración Psiquiátrica , Clorhidrato de VenlafaxinaRESUMEN
OBJECTIVE: Social phobia is a chronic disorder with a higher prevalence among women than men. Data from an eight-year longitudinal study were analyzed to investigate the course of social phobia and to explore potential sex differences in the course and characteristics of the illness. METHODS: Data were analyzed from the Harvard/Brown Anxiety Research Program, a naturalistic, observational study begun in 1989 in which patients with social phobia are assessed every six to 12 months. Treatment was observed but not prescribed by the program personnel. Data on comorbidity, remission, and health-related quality of life were collected for 176 patients with social phobia. RESULTS: Only 38 percent of women and 32 percent of men experienced a complete remission during the eight-year study period, a difference that was not significant. A larger proportion of women than men had the generalized form of social phobia, although the difference was not significant. Women were more likely to have concurrent agoraphobia, and men had a higher rate of comorbid substance use disorders. Social phobia had a more chronic course among women who had low Global Assessment of Functioning scores and a history of suicide attempts at baseline than among men who had these characteristics. Health-related quality of life was similar for both men and women, except that women were slightly but significantly more impaired in household functioning. CONCLUSIONS: The chronicity of social phobia was striking for both men and women. Although remission rates did not differ significantly between men and women, clinicians should be alert to the fact that women with poor baseline functioning and a history of suicide attempts have the greatest chronicity of illness.
Asunto(s)
Trastorno de Pánico/rehabilitación , Trastornos Fóbicos/rehabilitación , Resultado del Tratamiento , Actividades Cotidianas , Adolescente , Adulto , Comorbilidad , Femenino , Humanos , Estudios Longitudinales , Masculino , Massachusetts , Persona de Mediana Edad , Trastorno de Pánico/clasificación , Trastorno de Pánico/complicaciones , Trastornos Fóbicos/clasificación , Trastornos Fóbicos/complicaciones , Pronóstico , Estudios Prospectivos , Escalas de Valoración Psiquiátrica , Calidad de Vida , Inducción de Remisión , Factores SexualesRESUMEN
Women have a higher prevalence of GAD than do men. This ratio holds true in most clinical and general-population samples. Some variations exist, with evidence to suggest the strong impact of environment and life events. Women are sensitive to lifetime adversity and exacerbation of symptoms in conjunction with their menstrual cycle. Comorbidity is a crucial diagnostic factor when treating anyone with GAD, especially women. Most notably, high comorbidity with other anxiety disorders, MDD and alcohol-abuse disorder occurs for women. Overall, although the prevalence of women with GAD is greater than that of men with GAD, the course of illness and prognosis are not qualitatively different. Across varied methodology, data suggest gender-related differences in the metabolism and potentially in the effects and side effects of the various benzodiazepines and antidepressant psychopharmacologic treatments of GAD. Additional research is needed to better understand these differences.
Asunto(s)
Trastornos de Ansiedad/diagnóstico , Adulto , Negro o Afroamericano/estadística & datos numéricos , Anciano , Trastornos de Ansiedad/epidemiología , Trastornos de Ansiedad/psicología , Comorbilidad , Trastorno Depresivo Mayor/epidemiología , Femenino , Hispánicos o Latinos/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Escalas de Valoración Psiquiátrica , Población Blanca/estadística & datos numéricosRESUMEN
BACKGROUND: Cross-sectional data show that generalised anxiety disorder (GAD) is a chronic condition with episodes lasting much longer than the six-month minimum required by DSM-III-R and DSM-IV. Although GAD is chronic, little is known about factors influencing illness duration. AIMS: To investigate variables that influence the clinical course of GAD. METHOD: A total of 167 patients with GAD participated in the Harvard-Brown Anxiety Research Program. Patients were assessed at intake and re-examined at six- to twelve-month intervals for five years. Kaplan-Meier curves were constructed to assess the likelihood of remission. Regression analysis was used to investigate factors predicting full or partial remission. RESULTS: The rate of remission was 0.38 after five years. Diminished likelihood of remission was associated with low overall life satisfaction, poor spousal or family relationships, a concurrent cluster B or C personality disorder and a low global assessment score. CONCLUSIONS: Full or partial remissions were less likely to occur in patients with poor relationships and personality disorders. These patients should be given more intensive and possibly multi-modal therapy.
Asunto(s)
Trastornos de Ansiedad/psicología , Adolescente , Adulto , Niño , Preescolar , Estudios Transversales , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Remisión Espontánea , Factores de TiempoRESUMEN
BACKGROUND: While the sex difference in prevalence rates of unipolar depression is well established, few studies have examined gender differences in clinical features of depression. Even less is known about gender differences in chronic forms of depression. METHODS: 235 male and 400 female outpatients with DSM-III-R chronic major depression or double depression (i.e., major depression superimposed on dysthymia) were administered an extensive battery of clinician-rated and self-report measures. RESULTS: Women were less likely to be married and had a younger age at onset and greater family history of affective disorder compared to men. Symptom profile was similar in men and women, with the exception of more sleep changes, psychomotor retardation and anxiety/somatization in women. Women reported greater severity of illness and were more likely to have received previous treatment for depression with medications and/or psychotherapy. Greater functional impairment was noted by women in the area of marital adjustment, while men showed more work impairment. LIMITATIONS: Since our population consisted of patients enrolling in a clinical trial, study exclusion criteria may have affected gender-related differences found. CONCLUSIONS: Chronicity of depression appears to affect women more seriously than men, as manifested by an earlier age of onset, greater family history of affective disorders, greater symptom reporting, poorer social adjustment and poorer quality of life. These findings represent the largest study to date of gender differences in a population with chronic depressive conditions.
Asunto(s)
Trastorno Depresivo Mayor/psicología , Adulto , Enfermedad Crónica , Trastorno Depresivo Mayor/diagnóstico , Femenino , Estado de Salud , Humanos , Masculino , Escalas de Valoración Psiquiátrica , Índice de Severidad de la Enfermedad , Factores SexualesRESUMEN
OBJECTIVE: The authors examined gender differences in treatment response to sertraline, a selective serotonin reuptake inhibitor (SSRI), and to imipramine, a tricyclic antidepressant, in chronic depression. METHOD: A total of 235 male and 400 female outpatients with DSM-III-R chronic major depression or double depression (i.e., major depression superimposed on dysthymia) were randomly assigned to 12 weeks of double-blind treatment with sertraline or with imipramine after placebo washout. RESULTS: Women were significantly more likely to show a favorable response to sertraline than to imipramine, and men were significantly more likely to show a favorable response to imipramine than to sertraline. Gender and type of medication were also significantly related to dropout rates; women who were taking imipramine and men who were taking sertraline were more likely to withdraw from the study. Gender differences in time to response were seen with imipramine, with women responding significantly more slowly than men. Comparison of treatment response rates by menopausal status showed that premenopausal women responded significantly better to sertraline than to imipramine and that postmenopausal women had similar rates of response to the two medications. CONCLUSIONS: Men and women with chronic depression show differential responsivity to and tolerability of SSRIs and tricyclic antidepressants. The differing response rates between the drug classes in women was observed primarily in premenopausal women. Thus, female sex hormones may enhance response to SSRIs or inhibit response to tricyclics. Both gender and menopausal status should be considered when choosing an appropriate antidepressant for a depressed patient.
Asunto(s)
Antidepresivos Tricíclicos/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Imipramina/uso terapéutico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Sertralina/uso terapéutico , Adulto , Anciano , Atención Ambulatoria , Enfermedad Crónica , Trastorno Depresivo/diagnóstico , Trastorno Depresivo/psicología , Método Doble Ciego , Trastorno Distímico/diagnóstico , Trastorno Distímico/tratamiento farmacológico , Trastorno Distímico/psicología , Estrógenos/fisiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pacientes Desistentes del Tratamiento , Placebos , Premenopausia/fisiología , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Factores Sexuales , Resultado del TratamientoRESUMEN
BACKGROUND: The objective of this study was to evaluate the pretreatment psychosocial functioning of women with premenstrual dysphoric disorder (PMDD) and the effect of sertraline treatment on psychosocial functioning in these patients. METHOD: Two hundred forty-three women recruited from 12 university-affiliated sites and meeting DSM-IV criteria for PMDD completed 1 cycle of single-blind placebo and were randomly assigned to flexible dose sertraline or placebo for 3 cycles. Psychosocial functioning was assessed by the Daily Record of Severity of Problems (DRSP), the Social Adjustment Scale (SAS), and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). RESULTS: SAS scores during the follicular phase were similar to SAS scores of community norms, whereas the pretreatment SAS and Q-LES-Q scores during the luteal phase were similar to scores of women with depressive disorders. Sertraline was significantly more effective than placebo in improving psychosocial functioning as measured by the SAS, the Q-LES-Q, and the 3 DRSP items of impaired productivity, interference with social activities, and interference with relationships with others. Improvement in psychosocial functioning assessed by SAS and Q-LES-Q correlated with improvement in symptomatology assessed by the Clinical Global Impressions-Improvement (CGI-I) scale and the Hamilton Rating Scale for Depression (HAM-D). Remitters (CGI-I score of 1) were more likely to function better at baseline and showed larger improvements in functioning and quality of life with treatment compared with nonremitters. CONCLUSION: Sertraline was superior to placebo in improving psychosocial functioning in women with PMDD as reflected by SAS, Q-LES-Q, and DRSP measures. Functional improvement correlated with improvement in premenstrual symptomatology and was apparent by the second cycle of treatment. Comparison of pretreatment SAS scores in women with PMDD with the scores of other populations of women documents the degree of luteal phase functional impairment in women with PMDD and a relative absence of follicular phase impairment.
Asunto(s)
Adaptación Psicológica , Síndrome Premenstrual/tratamiento farmacológico , Síndrome Premenstrual/psicología , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Sertralina/uso terapéutico , Ajuste Social , Adulto , Femenino , Fase Folicular , Estado de Salud , Humanos , Fase Luteínica , Registros Médicos , Persona de Mediana Edad , Placebos , Síndrome Premenstrual/diagnóstico , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Calidad de Vida , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
BACKGROUND: Women are overrepresented in samples of patients with rapid cycling bipolar disorder (RCBD). To explore whether menstrually related mood changes might account for this gender difference, we studied the relationship between menstrual cycle phase and mood in a sample of premenopausal women with rapid cycling bipolar disorder (RCBD). METHODS: Twenty-five women with RCBD completed daily self-rating forms indicating their mood and days of menstruation for a minimum of three months. The data were analyzed for each individual and for the group as a whole, categorically (depression, euthymia, and hypomania) and ordinally (0-100, with 0 being "most depressed ever felt" and 100 being "most manic"), with and without normalization of the menstrual cycle to a 28-day cycle. RESULTS: None of the group analyses showed a significant effect of menstrual cycle on mood. Although some women did exhibit significant relationships between menstrual cycle phase and categorical mood state, there was no consistent pattern to the relationship. CONCLUSIONS: There was no systematic relationship between menstrual cycle and mood in a sample of women with RCBD.
Asunto(s)
Afecto , Trastorno Bipolar/fisiopatología , Trastorno Bipolar/psicología , Ciclo Menstrual/psicología , Adulto , Distribución de Chi-Cuadrado , Femenino , Humanos , Autoevaluación (Psicología)RESUMEN
Women who suffer from severe dysphoric premenstrual complaints can now be accurately diagnosed. A diagnosis of premenstrual dysphoric disorder is best made by ruling out other psychiatric and general medical conditions and by collecting daily ratings of symptom expression across the menstrual cycle. Recent treatment findings support the use of (1) antidepressants that block the serotonin transporter, and (2) the benzodiazepine anxiolytic alprazolam. Medication administered only during the luteal phase of the cycle will result in substantial relief for patients suffering from severe premenstrual dysphoric disorder.
Asunto(s)
Síntomas Afectivos/tratamiento farmacológico , Síndrome Premenstrual/tratamiento farmacológico , Síntomas Afectivos/diagnóstico , Síntomas Afectivos/etiología , Alprazolam/uso terapéutico , Ansiolíticos/uso terapéutico , Antidepresivos/uso terapéutico , Femenino , Humanos , Síndrome Premenstrual/diagnóstico , Síndrome Premenstrual/psicología , Congéneres de la Progesterona/uso terapéuticoRESUMEN
Among unipolar mood disorders, major depressive disorder (MDD) has traditionally been the most widely studied. There is, however, an alarming lack of extant research on the more mild mood disorders. Recent findings indicate that, collectively, milder unipolar mood disorders, such as dysthymic disorder (DD), and conditions specific to women, such as premenstrual dysphoric disorder (PMDD) and postpartum depression, functionally impair a large population of women. The course, mechanisms, and treatments of these illnesses are outlined, and specific areas of concern, including current available treatment applicability, gender differences in psychiatric testing, and the use of biological markers for the detection of illness, are detailed. Directions for future research are presented.
Asunto(s)
Trastornos del Humor/psicología , Mujeres , Femenino , Humanos , Trastornos del Humor/diagnóstico , Trastornos del Humor/terapiaRESUMEN
BACKGROUND: Abnormal alpha 2-adrenergic receptor (AR) function is implicated in anxiety and depressive disorders. Premenstrual dysphoric disorder (PMDD) is characterized by anxiety and depressive symptoms, which may be associated with changes in alpha 2AR function. Previous studies on alpha 2AR function during phases of the menstrual cycle in controls and PMDD patients are inconsistent. METHODS: alpha 2AR function was examined in 16 PMDD patients and 15 controls during the follicular phase, and in 10 PMDD patients during late luteal phase. Antagonist-measured maximum binding capacity, agonist-measured receptor density in high- and low-conformational states, and agonist affinity to both states were measured. Coupling efficiency to Gi protein was estimated. RESULTS: There were no significant differences in coupling efficiency. PMDD patients had significantly low antagonist affinity; there were no differences in other binding parameters. There were no changes in alpha 2AR binding parameters between phases of menstrual cycle in PMDD women. alpha 2AR density and symptom severity were inversely related during the follicular phase in controls and patients. During luteal phase, alpha 2AR density correlated positively with symptom severity in patients. High follicular alpha 2AR density predicted more severe luteal symptoms in PMDD patients. CONCLUSIONS: These findings are discussed in view of the molecular biology of alpha 2AR, and their role in PMDD, anxiety, and depressive disorders.
Asunto(s)
Plaquetas/metabolismo , Subunidades alfa de la Proteína de Unión al GTP Gi-Go/sangre , Fase Luteínica/psicología , Ciclo Menstrual/psicología , Síndrome Premenstrual/metabolismo , Receptores Adrenérgicos alfa 2/sangre , Adulto , Factores de Edad , Femenino , Fase Folicular/psicología , Humanos , Fase Luteínica/sangre , Ciclo Menstrual/sangre , Persona de Mediana Edad , Síndrome Premenstrual/sangre , Escalas de Valoración PsiquiátricaRESUMEN
BACKGROUND: Sleep disturbances are common in major depressive disorder. In previous open-label trials, nefazodone improved sleep continuity and increased rapid eye movement (REM) sleep, while not affecting stage 3/4 sleep or REM latency: in contrast, fluoxetine suppressed REM sleep. This study compared the objective and subjective effects of nefazodone and fluoxetine on sleep. METHODS: This paper reports combined results of three identical, multisite, randomized, double-blind, 8-week, acute-phase trials comparing nefazodone (n = 64) with fluoxetine (n = 61) in outpatients with nonpsychotic major depressive disorder and insomnia. Sleep electroencephalographic (EEG) recordings were gathered at baseline and weeks 2, 4, and 8. Clinical ratings were obtained at weeks 1-4, 6, and 8. RESULTS: Nefazodone and fluoxetine were equally effective in reducing depressive symptoms; however, nefazodone differentially and progressively increased (while fluoxetine reduced) sleep efficiency and reduced (while fluoxetine increased) the number of awakenings in a linear fashion over the 8-week trial. Fluoxetine, but not nefazodone, prolonged REM latency and suppressed REM sleep. Nefazodone significantly increased total REM sleep time. Clinical evaluations of sleep quality were significantly improved with nefazodone compared with fluoxetine. CONCLUSIONS: Nefazodone and fluoxetine were equally effective antidepressants. Nefazodone was associated with normal objective, and clinician- and patient-rated assessments of sleep when compared with fluoxetine. These differential sleep EEG effects are consistent with the notion that nefazodone and fluoxetine may have somewhat different modes and spectra of action.
Asunto(s)
Atención Ambulatoria , Antidepresivos de Segunda Generación/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Fluoxetina/uso terapéutico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Sueño/efectos de los fármacos , Triazoles/uso terapéutico , Adulto , Antidepresivos de Segunda Generación/farmacología , Ritmo Circadiano/efectos de los fármacos , Comorbilidad , Trastorno Depresivo/epidemiología , Método Doble Ciego , Electroencefalografía/efectos de los fármacos , Femenino , Fluoxetina/farmacología , Humanos , Masculino , Persona de Mediana Edad , Piperazinas , Receptores de Serotonina/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Sueño/fisiología , Trastornos del Inicio y del Mantenimiento del Sueño/epidemiología , Sueño REM/efectos de los fármacos , Sueño REM/fisiología , Triazoles/farmacología , Vigilia/efectos de los fármacosRESUMEN
Abnormal beta2-adrenergic receptor coupling to Gs protein is implicated in depressive disorders. Steroid hormones and antidepressants modulate beta-adrenergic receptor coupling, which may relate to the therapeutic efficacy of antidepressants. We examined beta2-adrenergic receptors in 18 patients with premenstrual dysphoric disorder (PMDD), in 15 control subjects during the follicular phase and in 12 patients during late luteal phase. Antagonist-measured receptor density, agonist-measured receptor density in the high- and low-conformational states and agonist affinity to both states were measured. Coupling indices to Gs protein were determined from agonist-displacement experiments. Follicular beta2-adrenergic receptor density was higher in patients than in control subjects, with a trend for higher receptor density in the high-conformational state. The phase of menstrual cycle had no effect on beta2-adrenergic receptor regulation in PMDD. Exploratory correlations showed that the K(L)/K(H) ratio was related to anxiety ratings in control subjects and %R(H) was correlated with symptom severity in patients. In patients, follicular beta2-adrenergic receptor binding measures were correlated with luteal symptom severity. These findings suggest abnormal beta2-adrenergic receptor regulation in PMDD. Further exploration of the role of beta-adrenergic receptor kinase, sex steroid hormones and antidepressants on beta-adrenergic receptor regulation in PMDD is warranted.
Asunto(s)
Ansiedad/fisiopatología , Depresión/fisiopatología , Proteínas de Unión al GTP/fisiología , Síndrome Premenstrual/fisiopatología , Receptores Adrenérgicos beta 2/fisiología , Adulto , Ansiedad/sangre , Estudios de Casos y Controles , Depresión/sangre , Femenino , Fase Folicular/fisiología , Humanos , Radioisótopos de Yodo , Yodocianopindolol , Genio Irritable/fisiología , Fase Luteínica/fisiología , Persona de Mediana Edad , Pindolol/análogos & derivados , Síndrome Premenstrual/sangre , Unión Proteica/fisiología , Ensayo de Unión Radioligante , Receptores Adrenérgicos beta 2/química , Análisis de Regresión , Índice de Severidad de la Enfermedad , Regulación hacia Arriba/fisiologíaRESUMEN
OBJECTIVE: Panic disorder with or without agoraphobia has a chronic relapsing course. Factors associated with poor outcome include early onset of illness and phobic avoidance. Several, but not all, authors have found a worse clinical course for women. Using observational, longitudinal data from the Harvard/Brown Anxiety Disorders Research Program, the authors analyzed remission and symptom recurrence rates in panic patients with respect to sex. METHOD: Male and female patients (N = 412) in an episode of panic with or without agoraphobia were assessed by structured interview and prospectively followed for up to 5 years. Data on remission, symptom recurrence, and comorbid psychiatric conditions for each sex were compared. RESULTS: There were no significant differences between men and women in panic symptoms or level of severity at baseline. Women were more likely to have panic with agoraphobia (85% versus 75%), while men were more likely to have uncomplicated panic (25% versus 15%). The rates of remission for panic with or without agoraphobia at 5 years were equivalent in men and women (39%). Of the subjects who achieved remission, 25% of the women and 15% of the men reexperienced symptoms by 6 months. Recurrence of panic symptoms continued to be higher in women (82%) than men (51%) during the follow-up period and was not influenced by concurrent agoraphobia. CONCLUSIONS: This study extends previous findings by showing that not only are women more likely to have panic with concurrent agoraphobia, but they are more likely than men to suffer a recurrence of panic symptoms after remission of panic.
Asunto(s)
Trastorno de Pánico/diagnóstico , Edad de Inicio , Agorafobia/diagnóstico , Agorafobia/epidemiología , Alcoholismo/diagnóstico , Alcoholismo/epidemiología , Comorbilidad , Femenino , Estudios de Seguimiento , Humanos , Estudios Longitudinales , Masculino , Trastornos Mentales/diagnóstico , Trastornos Mentales/epidemiología , Trastorno de Pánico/epidemiología , Probabilidad , Estudios Prospectivos , Escalas de Valoración Psiquiátrica/estadística & datos numéricos , Recurrencia , Índice de Severidad de la Enfermedad , Factores Sexuales , Resultado del TratamientoRESUMEN
Lithium is used as a primary treatment or augmentation therapy for several psychiatric conditions, such as bipolar depression, mania and unipolar depression. For many patients with bipolar disorder, it is the most effective mood stabiliser.More than half of the patients maintained on lithium are women, and many are of reproductive age. An unknown proportion of women who are receiving lithium maintenance therapy become pregnant, posing numerous clinical issues for the obstetrician, psychiatrist and patient. The specific problems associated with lithium exposure vary during different stages of gestation. The risk of the serious heart defect, Ebstein's anomaly, exists if the drug is taken during weeks 2 to 6 post-conception; risks of fetal/neonatal complications occur if lithium is taken during the second and third trimesters.Given the effects of lithium on the conceptus, potentially safer alternatives may be required. The best case scenario is to counsel fecund women who require lithium to plan pregnancy, allowing for a temporary change in treatment regimen during the period of embryogenesis. If lithium therapy is reinstituted during the second and third trimesters, fetal monitoring for altered renal and endocrine function is important. Lithium requirements usually increase in the third trimester, but should be decreased in the peripartum period to avoid drug toxicity in the neonate and mother. Ultimately, the risk/benefit considerations must guide clinicians and patients in the decision to use lithium during pregnancy.
RESUMEN
CONTEXT: Premenstrual dysphoric disorder is an important cause of symptoms and functional impairment in menstruating women. OBJECTIVE: To evaluate the efficacy of sertraline hydrochloride for treatment of premenstrual dysphoria by measuring changes in symptom expression and functional impairment. DESIGN: Two screening cycles followed by 1 single-blind placebo cycle and 3 cycles of randomized, double-blind, placebo treatment. SETTING: Twelve university-affiliated outpatient psychiatry and gynecology clinics. PATIENTS: Of the 447 women who requested participation, 243 met criteria for premenstrual dysphoric disorder and were randomized; 200 women completed the study. INTERVENTION: A flexible (50-150 mg) daily dose of sertraline hydrochloride. MAIN OUTCOME MEASURES: The Daily Record of Severity of Problems, Hamilton Rating Scale for Depression, Clinical Global Impression Scale, and Social Adjustment Scale. RESULTS: Mean (+/-SD) total daily symptom scores decreased significantly (P<.001) in the sertraline-treated (64+/-22 to 44+/-19) compared with the placebo-treated (62+/-22 to 54+/-24) groups. Significant improvement (P<.05) was found for all clinically derived symptom clusters (depressive, physical, and anger/irritability symptoms). Hamilton Rating Scale for Depression scores decreased by 44% and 29% in the sertraline and placebo groups, respectively (P<.002). End-point global ratings showed much or very much improvement in 62% of the active treatment group and 34% of the placebo treatment group (P<.001). Reported functional impairment was substantial at baseline. Improvement in psychosocial functioning with treatment was similar to what is found in studies of major depression. CONCLUSIONS: Sertraline was significantly better than placebo for treatment of premenstrual dysphoria as reflected by symptomatic improvement and change in reported functional impairment. Serotonin reuptake inhibitors such as sertraline are useful therapeutic options for women with premenstrual dysphoria.